Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Most women requesting pregnancy termination have already decided to undergo an abortion, but some jurisdictions have implemented strategies to induce doubt and regret.
AMA J Ethics. 2020;22(9):E792-795. doi:
10.1001/amajethics.2020.792.
Workplace wellness programs contribute to the wellness movement by enlisting nontraditional health partners and influencing social determinants of health.
AMA J Ethics. 2016;18(4):393-398. doi:
10.1001/journalofethics.2016.18.4.nlit1-1604.
Distinguishing between elective and therapeutic abortions undermines the moral agency of patients and disproportionately amplifies moral rather than medical dimensions of the procedure.
AMA J Ethics. 2018;20(12):E1175-1180. doi:
10.1001/amajethics.2018.1175.
Physicians should provide women considering abortion after Down syndrome screening with unbiased information and not attempt to influence their decision.
AMA J Ethics. 2016;18(4):359-364. doi:
10.1001/journalofethics.2016.18.4.ecas1-1604.